Red Blood Cell Transfusion Strategies in Adult and Pediatric Patients with Malignancy

Hematology/Oncology Clinics of North America

Volumn 30, Issue 3, 2016, Pages 529-540

  Roubinian, Nareg ^a,b   Carson, Jeffrey L ^c  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Bleeding; Malignancy; Randomized clinical trials; RBC transfusion

Indexed keywords

RECOMBINANT ERYTHROPOIETIN; HEMOGLOBIN;

ABDOMINAL INFECTION; ACUTE LUNG INJURY; ANEMIA; CARDIOVASCULAR DISEASE; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL HEMORRHAGE; HEMOLYSIS; HUMAN; IMMUNOMODULATION; IRON OVERLOAD; MORTALITY RATE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SEPTIC SHOCK; TREATMENT OUTCOME; ADOLESCENT; ADULT; BLOOD; CHILD; CLINICAL TRIAL (TOPIC); FEMALE; HEMORRHAGE; INFANT; INFECTION; MALE; METABOLISM; NEOPLASMS; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANEMIA; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBINS; HEMORRHAGE; HUMANS; INFANT; INFECTION; MALE; NEOPLASMS; QUALITY OF LIFE;

EID: 84958568681     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2016.01.001     Document Type: Review

References (51)

1. Ludwig H., van Belle S., Barrett-Lee P., et al. The European cancer anaemia survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004, 40(15):2293-2306.
2. Maccio A., Madeddu C., Gramignano G., et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica 2015, 100(1):124-132.
3. Roy C.N., Andrews N.C. Anemia of inflammation: the hepcidin link. Curr Opin Hematol 2005, 12(2):107-111.
4. Rodgers G.M., Becker P.S., Blinder M., et al. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 2012, 10(5):628-653.
5. Groopman J.E., Itri L.M. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999, 91(19):1616-1634.
6. Michon J. Incidence of anemia in pediatric cancer patients in Europe: results of a large, international survey. Med Pediatr Oncol 2002, 39(4):448-450.
7. Gilreath J.A., Stenehjem D.D., Rodgers G.M. Diagnosis and treatment of cancer-related anemia. Am J Hematol 2014, 89(2):203-212.
8. Birgegard G. Managing anemia in lymphoma and multiple myeloma. Ther Clin Risk Manag 2008, 4(2):527-539.
9. Carson J.L., Grossman B.J., Kleinman S., et al. Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2012, 157(1):49-58.
10. Killick S.B., Carter C., Culligan D., et al. Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Br J Haematol 2014, 164(4):503-525.
11. Vallet B., Adamczyk S., Barreau O., et al. Physiologic transfusion triggers. Best Pract Res Clin Anaesthesiol 2007, 21(2):173-181.
12. Pinchon D.J., Stanworth S.J., Doree C., et al. Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review. Am J Hematol 2009, 84(10):671-677.
13. Goodnough L.T., Levy J.H., Murphy M.F. Concepts of blood transfusion in adults. Lancet 2013, 381(9880):1845-1854.
14. Vamvakas E.C. Transfusion-associated cancer recurrence and postoperative infection: meta-analysis of randomized, controlled clinical trials. Transfusion 1996, 36(2):175-186.
15. Vamvakas E.C., Blajchman M.A. Transfusion-related immunomodulation (TRIM): an update. Blood Rev 2007, 21(6):327-348.
16. Carson J.L., Duff A., Poses R.M., et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet 1996, 348(9034):1055-1060.
17. Carson J.L., Noveck H., Berlin J.A., et al. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion 2002, 42(7):812-818.
18. Wu W.C., Schifftner T.L., Henderson W.G., et al. Preoperative hematocrit levels and postoperative outcomes in older patients undergoing noncardiac surgery. JAMA 2007, 297(22):2481-2488.
19. Musallam K.M., Tamim H.M., Richards T., et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet 2011, 378(9800):1396-1407.
20. Vogelzang N.J., Breitbart W., Cella D., et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997, 34(3 Suppl 2):4-12.
21. Carson J.L., Carless P.A., Hebert P.C. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2012, (4). CD002042.
22. Holst L.B., Petersen M.W., Haase N., et al. Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis. BMJ 2015, 350:h1354.
23. Hebert P.C., Wells G., Blajchman M.A., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group [see comments]. N Engl J Med 1999, 340(6):409-417.
24. Holst L.B., Haase N., Wetterslev J., et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 2014, 371(15):1381-1391.
25. Lacroix J., Hebert P.C., Hutchison J.S., et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med 2007, 356(16):1609-1619.
26. Kirpalani H., Whyte R.K., Andersen C., et al. The premature infants in need of transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants. J Pediatr 2006, 149(3):301-307.
27. Mannucci P.M. Overview of bleeding in cancer patients. Pathophysiol Haemost Thromb 2003, 33(Suppl 1):44-45.
28. Villanueva C., Colomo A., Bosch A., et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013, 368(1):11-21.
29. Jairath V., Kahan B.C., Gray A., et al. Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet 2015, 386(9989):137-144.
30. Valeri C.R., Cassidy G., Pivacek L.E., et al. Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss. Transfusion 2001, 41(8):977-983.
31. Webert K.E., Cook R.J., Couban S., et al. A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion 2008, 48(1):81-91.
32. Tay J., Tinmouth A., Fergusson D., et al. Transfusion of red cells in hematopoietic stem cell transplantation (TRIST): study protocol for a randomized controlled trial. Trials 2011, 12:207.
33. Carson J.L., Terrin M.L., Noveck H., et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med 2011, 365(26):2453-2462.
34. Brunskill S.J., Millette S.L., Shokoohi A., et al. Red blood cell transfusion for people undergoing hip fracture surgery. Cochrane Database Syst Rev 2015, (4). CD009699.
35. de Almeida J.P., Vincent J.L., Galas F.R., et al. Transfusion requirements in surgical oncology patients: a prospective, randomized controlled trial. Anesthesiology 2015, 122(1):29-38.
36. Rohde J.M., Dimcheff D.E., Blumberg N., et al. Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. JAMA 2014, 311(13):1317-1326.
37. Murphy G.J., Pike K., Rogers C.A., et al. Liberal or restrictive transfusion after cardiac surgery. N Engl J Med 2015, 372(11):997-1008.
38. Yeh E.T., Tong A.T., Lenihan D.J., et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004, 109(25):3122-3131.
39. Bracey A.W., Radovancevic R., Riggs S.A., et al. Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome. Transfusion 1999, 39(10):1070-1077.
40. Hajjar L.A., Vincent J.L., Galas F.R., et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA 2010, 304(14):1559-1567.
41. Cooper H.A., Rao S.V., Greenberg M.D., et al. Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT randomized pilot study). Am J Cardiol 2011, 108(8):1108-1111.
42. Carson J.L., Brooks M.M., Abbott J.D., et al. Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J 2013, 165(6):964-971.
43. Rizzo J.D., Brouwers M., Hurley P., et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010, 28(33):4996-5010.
44. Seidenfeld J., Piper M., Flamm C., et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001, 93(16):1204-1214.
45. Corwin H.L., Gettinger A., Fabian T.C., et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007, 357(10):965-976.
46. Littlewood T.J., Bajetta E., Nortier J.W., et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001, 19(11):2865-2874.
47. Hedley B.D., Allan A.L., Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res 2011, 17(20):6373-6380.
48. Bennett C.L., Silver S.M., Djulbegovic B., et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008, 299(8):914-924.
49. Gabrilove J.L., Cleeland C.S., Livingston R.B., et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001, 19(11):2875-2882.
50. Bokemeyer C., Aapro M.S., Courdi A., et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007, 43(2):258-270.
51. Spitalnik S.L., Triulzi D., Devine D.V., et al. 2015 proceedings of the national heart, lung, and blood institute's state of the science in transfusion medicine symposium. Transfusion 2015, 55(9):2282-2290.